Although the critical role of the PD1/PDL-1 axis in the initial phase of tumor progression, several other immune parameters were evaluated in NSCLC patients as possible biomarkers not only in the tumor, but also in the peripheral blood. This evidence concerns the gene CD274 and non-small cell lung carcinoma.